Study of the Glutaminase Inhibitor CB-839 in Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with leukemia.

This study is an open-label Phase 1 evaluation of CB-839 in subjects with leukemia. Part 1 is a dose escalation study to identify the recommended Phase 2 dose as a single agent and in combination with azacitidine. Patients enrolled into Part 2 will be treated with the recommended Phase 2 dose. As an extension of Part 2, patients with relapsed/ refractory or newly diagnosed AML will be treated with CB-839 in combination with azacitidine.

All patients will be assessed for safety, pharmacokinetics (plasma concentration of drug), pharmacodynamics (inhibition of glutaminase), biomarkers (biochemical markers that may predict responsiveness in later studies), and tumor response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071888

Non-Hodgkin's Lymphoma (NHL) Multiple Myeloma Waldenstrom's Macroglobulinemia (WM) +2 more

COMPLETED PHASE1

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

NCT00890929

Acute Myeloid Leukemia (AML) Adult Acute Myeloblastic Leukemia

COMPLETED PHASE1/PHASE2

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

NCT01519011

Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Leukemia, Myeloid, Acute

COMPLETED PHASE1

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

NCT01019161

Acute Myeloid Leukaemia

COMPLETED PHASE1

A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients

NCT07303660

Acute Myeloid Leukemia

NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia (AML) Acute Lymphocytic Leukemia (ALL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CB-839

CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity

Group Type EXPERIMENTAL

CB-839

Intervention Type DRUG

Single-agent CB-839

CB-Aza

CB-839 administered as oral capsules twice daily (BID) in combination with azacitidine in 28-day cycles until disease progression or unacceptable toxicity

Group Type EXPERIMENTAL

CB-839

Intervention Type DRUG

Single-agent CB-839

CB-Aza

Intervention Type DRUG

CB-839 in combination with standard dose azacitidine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CB-839

Single-agent CB-839

Intervention Type DRUG

CB-Aza

CB-839 in combination with standard dose azacitidine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glutaminase inhibitor combo CB-839 and azacitidine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of AML or ALL, relapsed or refractory after at least 1 prior treatment regimen. Newly-diagnosed patients ≥ 60 years old who have refused or are considered unfit for standard chemotherapy regimens or stem cell transplantation are also eligible.
* Patients must have no available approved therapies that confer clinical benefit
* All patients must have bone marrow involvement of their tumor, with documented blast percentage of \> 5%.
* Peripheral blood blast count must be ≤ 30,000 cells/µL.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
* Adequate hepatic, renal, and cardiac function

Exclusion Criteria

* Any other current malignancy
* Patients with acute promyelocytic leukemia (APL)
* Treatment with an unapproved, investigational agent within 21 days of the first dose of study drug
* Allogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within 90 days prior to to the first dose of study drug
* Active GVHD
* Unable to receive medications by mouth
* Major surgery within 28 days before Cycle 1 Day 1
* Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation
* Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to Day 1
* Refractory nausea and vomiting or other situation that may preclude adequate absorption
* Conditions that could interfere with treatment and procedures

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No